DK1007512T3 - Forgrenede alkoxysubstituerede 2-aminopyridiner som NOS-inhibitorer - Google Patents

Forgrenede alkoxysubstituerede 2-aminopyridiner som NOS-inhibitorer

Info

Publication number
DK1007512T3
DK1007512T3 DK98935247T DK98935247T DK1007512T3 DK 1007512 T3 DK1007512 T3 DK 1007512T3 DK 98935247 T DK98935247 T DK 98935247T DK 98935247 T DK98935247 T DK 98935247T DK 1007512 T3 DK1007512 T3 DK 1007512T3
Authority
DK
Denmark
Prior art keywords
aminopyridines
substituted
branched alkoxy
nos inhibitors
inhibitors
Prior art date
Application number
DK98935247T
Other languages
English (en)
Inventor
John Adams Lowe Iii
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1007512T3 publication Critical patent/DK1007512T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
DK98935247T 1997-08-28 1998-08-11 Forgrenede alkoxysubstituerede 2-aminopyridiner som NOS-inhibitorer DK1007512T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5773997P 1997-08-28 1997-08-28
PCT/IB1998/001223 WO1999011620A1 (en) 1997-08-28 1998-08-11 Branched alkoxy-subsituted 2-aminopyridines as nos inhibitors

Publications (1)

Publication Number Publication Date
DK1007512T3 true DK1007512T3 (da) 2002-07-08

Family

ID=22012464

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98935247T DK1007512T3 (da) 1997-08-28 1998-08-11 Forgrenede alkoxysubstituerede 2-aminopyridiner som NOS-inhibitorer

Country Status (32)

Country Link
US (2) US6362195B1 (da)
EP (1) EP1007512B1 (da)
JP (1) JP3441714B2 (da)
CN (1) CN1268122A (da)
AP (1) AP9801331A0 (da)
AR (1) AR016644A1 (da)
AT (1) ATE215532T1 (da)
AU (1) AU8458698A (da)
BR (1) BR9811921A (da)
CA (1) CA2302436C (da)
DE (1) DE69804635T2 (da)
DK (1) DK1007512T3 (da)
EA (1) EA200000165A1 (da)
ES (1) ES2172173T3 (da)
GT (1) GT199800135A (da)
HN (1) HN1998000125A (da)
HR (1) HRP980476A2 (da)
HU (1) HUP0002803A2 (da)
ID (1) ID24318A (da)
IL (1) IL134302A0 (da)
IS (1) IS5342A (da)
MA (1) MA26538A1 (da)
NO (1) NO20000957D0 (da)
OA (1) OA11294A (da)
PA (1) PA8458301A1 (da)
PE (1) PE106699A1 (da)
PL (1) PL339008A1 (da)
PT (1) PT1007512E (da)
SI (1) SI1007512T1 (da)
TN (1) TNSN98157A1 (da)
WO (1) WO1999011620A1 (da)
ZA (1) ZA987788B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049379A1 (en) 1997-08-27 2001-12-06 Lowe John Adams 2-aminopyridines containing fused ring substituents
HUP0103113A3 (en) * 1998-08-11 2002-02-28 Pfizer Prod Inc New pharmaceutical compositions uses for nos inhibitors
CA2364719C (en) 1999-02-25 2006-07-04 Pfizer Products Inc. 2-aminopyridines containing fused ring substituents
WO2001009307A2 (en) * 1999-07-30 2001-02-08 University College London Screen for nitric oxide synthase modulators
EP1203098A2 (en) * 1999-07-30 2002-05-08 University College London Inducible screen for drug discovery
GB0004151D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004149D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004153D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004152D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
US6469172B2 (en) * 2000-03-08 2002-10-22 Merck & Co., Inc. Process for the preparation of chemical compounds
SE0102640D0 (sv) 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
US20040077853A1 (en) * 2001-10-10 2004-04-22 Pfizer Inc. 2-amino-6-(2,4,5-substituted-phenyl)-pyridines
AU2003241398A1 (en) * 2002-05-06 2003-11-17 Washington University Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
WO2005007627A1 (ja) * 2003-07-18 2005-01-27 Nihon Nohyaku Co., Ltd. フェニルピリジン誘導体、その中間体及びこれを有効成分とする除草剤
WO2006053109A1 (en) * 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
US8604031B2 (en) * 2006-05-18 2013-12-10 Mannkind Corporation Intracellular kinase inhibitors
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
EP3002279A1 (de) 2014-10-02 2016-04-06 Bayer CropScience AG Verfahren zur Herstellung von 3-(5-Aminotriazolyl)-Sulfid-Derivaten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
AU4515696A (en) * 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
US5972975A (en) * 1995-12-08 1999-10-26 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
JP4431638B2 (ja) * 1996-01-29 2010-03-17 アメリカ合衆国 ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途
NZ326874A (en) * 1996-03-29 2000-01-28 Pfizer 6-phenylpyridyl-2-amine derivatives
HN1997000027A (es) * 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina

Also Published As

Publication number Publication date
AR016644A1 (es) 2001-07-25
US6362195B1 (en) 2002-03-26
WO1999011620A1 (en) 1999-03-11
IS5342A (is) 2000-01-14
CA2302436A1 (en) 1999-03-11
PA8458301A1 (es) 2000-05-24
DE69804635T2 (de) 2002-07-18
ES2172173T3 (es) 2002-09-16
DE69804635D1 (de) 2002-05-08
NO20000957L (no) 2000-02-25
BR9811921A (pt) 2000-08-15
EA200000165A1 (ru) 2000-10-30
ZA987788B (en) 2000-02-28
NO20000957D0 (no) 2000-02-25
PE106699A1 (es) 1999-11-02
IL134302A0 (en) 2001-04-30
JP3441714B2 (ja) 2003-09-02
ID24318A (id) 2000-07-13
HN1998000125A (es) 1999-02-09
AP9801331A0 (en) 2000-02-27
OA11294A (en) 2003-10-22
US20020022642A1 (en) 2002-02-21
ATE215532T1 (de) 2002-04-15
AU8458698A (en) 1999-03-22
CN1268122A (zh) 2000-09-27
TNSN98157A1 (fr) 2005-03-15
EP1007512B1 (en) 2002-04-03
PT1007512E (pt) 2002-07-31
JP2001514252A (ja) 2001-09-11
HRP980476A2 (en) 1999-06-30
SI1007512T1 (en) 2002-10-31
PL339008A1 (en) 2000-12-04
MA26538A1 (fr) 2004-12-20
HUP0002803A2 (hu) 2001-06-28
GT199800135A (es) 2000-02-08
CA2302436C (en) 2003-10-07
EP1007512A1 (en) 2000-06-14

Similar Documents

Publication Publication Date Title
NO992725L (no) 6-Fenylpyridyl-2-amin-derivater anvendelige som NOS-inhibitorer
DK1007520T3 (da) 2-aminopyridiner som indeholder sammensluttede ringsubstituenter som NOS inhibitorer
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
NO986090D0 (no) Fenylalaninderivater som integrininhibitorer
DK1930330T3 (da) Pleuromutilinderivater som antimikrobielle midler
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
NO992821D0 (no) Ketobenzamider som calpain-inhibitorer
NO983669D0 (no) Coralyne analoger som topoisomeraseinhibitorer
NO20000957D0 (no) Forgrenede alkoksy-substituerte 2-aminopyridiner som NOS inhibitorer
DK1049695T3 (da) 2-Phenyl-substituerede imidazotriazinoner som phosphodiesterase-inhibitorer
NO20012156D0 (no) Pyrazolopyridinderivater som selektive COX-2 inhibitorer
NO20002162D0 (no) Tienopyrimidin- og tienopyridinderivater nyttige som anticancer midler
DK0818448T3 (da) Cycloalkanopyridiner som CETP-inhibitorer
DK1097127T3 (da) Diacylhydrazinderivater som integrininhibitorer
DK0975623T3 (da) Indazolamidforbindelser som sertoninerge midler
NO991560D0 (no) PDE IV som inhiberer 2-cyanoiminoimidazol-derivater
NO20010331D0 (no) Ftalazinderivater som fosfodiesterase 4-inhibitorer
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
NO20001924L (no) Isoquinoliner som urokinase-inhibitorer
NO20021959L (no) Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
DK0747346T3 (da) N-acyl-2-arylcyclopropylmethylaminderivater som melatonerge midler
DK1075471T3 (da) Idolylderivater som serotonerge midler
NO20002321D0 (no) Bifenylderivater som farmasøytiske midler
NO20000094D0 (no) 6-Azaurcilderivater som IL-5 inhibitorer
DK1077945T3 (da) Isoquinoliner som urokinaseinhibitorer